3.900USD-0.76%Mkt Cap: —P/E: —1d ago
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new the…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value-11.59M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-16.50M $
Revenue/Share—
Last Price3.900 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees13
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS3724461047
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.14
EPS (TTM)-0.40
EPS (Forward)—
52W Range
3.7005% of range7.360
52W High7.360 USD
52W Low3.700 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-203.86%
ROA-94.46%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.56M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-15.15M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio6.76
Quick Ratio6.47
Book Value/Sh29.23 USD
Cash/Share18.49 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.045455:1
Split DateJul 16, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float818.03K
Insiders0.21%
Institutions1.74%
Technical
SMA 501.592 (+145.0%)
SMA 2001.041 (+274.7%)
Beta—
S&P 52W Chg20.80%
Avg Vol (30d)7.49K
Avg Vol (10d)397
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—